ZBIO's Quality Score rose 2 points on Fri, Nov 6, to -2. Its price climbed back above its average of the last 200 days.
Follow ZBIO's trial news. Pro members can get an alert when Zenas BioPharma files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 9% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%.
| Holding it back | Sales down 80% |
| Latest filing | 424B5, Nov 6 |
After its last 4 reports it closed -3.7% on average, higher 1 of 4 times.
About 11 quarters
CEO Leon O Moulder Jr bought 60,000 shares on May 18. 9 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
ZBIO is #159 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 159 |
Expected to report Tue Mar 16, before the open (in 127 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $1.65 a share, from $1.22.
“The increase of $24.1 million in R&D expenses was primarily due to an increase in costs related to clinical trial and regulatory costs for the orelabrutinib and obexelimab programs and an increase in personnel costs including stock-based compensation expense primarily due to an”
ZBIO's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase of $14.3 million in G&A expenses was primarily due to an increase in personnel costs, including stock-based compensation expense primarily due to the modification of stock options related the transition and separation of certain employees from the company, an increase in salary”
From its results filing (SEC filing · Nov 5)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | -1.3% | -8.9% | not yet |
| Aug 13, 2026 | -2.9% | -6.7% | -0.1% |
| May 13, 2026 | +2.3% | +4.0% | -6.9% |
Sales grew in one of the last two years, to $10M in 2025. It lost money in each of the three years.
RSI 51.6, MACD above signal, below its 50-day, above its 200-day. Not scored.
One insider bought $1M across 1 filing in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ZBIO is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
“The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary drugs.”
ZBIO scores -2 today, which Breakaway calls Poor. It is #159 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 9% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%. Cash lasts about 11 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ZBIO scores -2 today, which Breakaway calls Poor (below zero). That is #159 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ZBIO's -2.
One insider bought $1M across 1 filing in the last 6 months. No open-market sales on record. The newest is Leon O. Moulder Jr., Chief Executive Officer, who bought $1M on May 18.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.